# CT45A8

## Overview
CT45A8 is a gene that encodes the protein cancer/testis antigen family 45 member A8, which is part of the cancer/testis antigen family. These proteins are typically expressed in the testis and various cancer types, making them of particular interest in oncology for their potential as biomarkers and therapeutic targets. The CT45A8 protein is implicated in oncogenic pathways, including TGF-β/SMAD signaling, and its expression is associated with disease progression and metastatic profiles in certain cancers, such as prostate cancer (GarcíaOlivares2021Regulation). Additionally, CT45A8 is involved in processes like snRNA processing and hormone-mediated signaling pathways in esophageal cancer, although its specific role in this context requires further elucidation (Zhang2022Altered). The differential expression of CT45A8 in various malignancies underscores its potential utility in cancer diagnosis and prognosis, as well as its promise as a target for therapeutic intervention.

## Clinical Significance
CT45A8, a member of the cancer/testis antigen family, is implicated in various cancers due to its aberrant expression. In prostate cancer, CT45A8 is downregulated by a combinatory treatment of calcitriol and TGF-β, which is associated with the inhibition of cell proliferation. This suggests that CT45A8 may play a role in oncogenic pathways, including TGF-β/SMAD signaling, and its expression is linked to disease progression and metastatic profiles (GarcíaOlivares2021Regulation).

In esophageal cancer, CT45A8 is mentioned in the context of hyper-DhMRs, which are enriched in processes like snRNA processing and hormone-mediated signaling pathways. However, the specific clinical significance of CT45A8 in this cancer type is not detailed (Zhang2022Altered).

Overall, the altered expression of CT45A8 in various cancers highlights its potential as a biomarker for diagnosis and prognosis. Its involvement in cancer-related signaling pathways suggests that targeting CT45A8 could be a viable strategy for therapeutic interventions in cancers where it is aberrantly expressed.


## References


[1. (GarcíaOlivares2021Regulation) Mitzi García-Olivares, Sandra Romero-Córdoba, Elizabeth Ortiz-Sánchez, Rocío García-Becerra, Mariana Segovia-Mendoza, Claudia Rangel-Escareño, Ali Halhali, Fernando Larrea, and David Barrera. Regulation of anti-tumorigenic pathways by the combinatory treatment of calcitriol and tgf-β in pc-3 and du145 cells. The Journal of Steroid Biochemistry and Molecular Biology, 209:105831, May 2021. URL: http://dx.doi.org/10.1016/j.jsbmb.2021.105831, doi:10.1016/j.jsbmb.2021.105831. This article has 4 citations.](https://doi.org/10.1016/j.jsbmb.2021.105831)

[2. (Zhang2022Altered) Xianjing Zhang, Mingzhu Lu, Jing Zhu, Changsong Zhang, and Meihua Wang. Altered genome‑wide hydroxymethylation analysis for neoadjuvant chemoradiotherapy followed by surgery in esophageal cancer. Experimental and Therapeutic Medicine, November 2022. URL: http://dx.doi.org/10.3892/etm.2022.11728, doi:10.3892/etm.2022.11728. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/etm.2022.11728)